Training the host organism to enhance anti-cancer immunity

Miriam Ferrer; Tobias Janowitz

doi:10.1016/j.ccell.2022.06.003

Training the host organism to enhance anti-cancer immunity

Cancer Cell. 2022 Jul 11;40(7):703-705. doi: 10.1016/j.ccell.2022.06.003. Epub 2022 Jun 23.

Authors

Miriam Ferrer¹, Tobias Janowitz²

Affiliations

¹ Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; MRC Cancer Unit, University of Cambridge, Cambridge, UK.
² Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; Northwell Health Cancer Institute, New York, NY, USA. Electronic address: janowitz@cshl.edu.

PMID: 35750051
DOI: 10.1016/j.ccell.2022.06.003

Abstract

In this issue of Cancer Cell, Kurz et al. demonstrate in an orthotopic pancreatic cancer model that low-intensity exercise improves tumor control and response to immunotherapy in an IL-15-dependent manner. Combination therapy, IL-15 super-agonist, anti-PD-1 antibody and chemotherapy, strongly reduces tumor growth. Therefore, the study opens rich translational avenues.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cell Line, Tumor
Combined Modality Therapy
Humans
Immunotherapy
Interleukin-15* / therapeutic use
Pancreatic Neoplasms* / drug therapy
Tumor Microenvironment

Substances

Interleukin-15

Grants and funding

P30 CA045508/CA/NCI NIH HHS/United States